Vanda Pharmaceuticals (VNDA) Operating Expenses (2010 - 2026)

Vanda Pharmaceuticals (VNDA) has 17 years of Operating Expenses data on file, last reported at $101.9 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses rose 11.94% year-over-year to $101.9 million; the trailing twelve-month figure through Mar 2026 stood at $378.1 million (up 38.11% YoY), and the FY2025 full-year result was $367.3 million, up 53.39% from the prior year.
• Operating Expenses advanced to $101.9 million in Q1 2026, from $97.6 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $101.9 million in Q1 2026 to a low of $44.8 million in Q3 2023.
• A 5-year average of $68.4 million and a median of $60.9 million in 2022 frame the typical range for Operating Expenses.
• Across the five-year window, Operating Expenses fell 27.03% in 2023 and jumped 60.62% in 2025, its largest moves.
• Tracing VNDA's Operating Expenses over 5 years: stood at $57.9 million in 2022, then retreated by 9.49% to $52.4 million in 2023, then advanced by 21.2% to $63.5 million in 2024, then jumped by 53.74% to $97.6 million in 2025, then gained by 4.48% to $101.9 million in 2026.
• Business Quant data shows VNDA's Operating Expenses at $101.9 million in Q1 2026, $97.6 million in Q4 2025, and $87.5 million in Q3 2025.